Trials / Completed
CompletedNCT01983293
CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients
Cardiac Resynchronization Therapy (CRT) Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). A Prospective, Randomized, Postmarket, Pilot Study.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to analyze the effect of left ventricular lead pacing location in the non-left bundle branch block (non-LBBB) heart failure patient population. The left ventricular lead pacing location will be guided by either the pacing site with the largest amount of dyssynchrony as measured by the LV electrical delay (QLV) or the physician's standard of care implant approach.
Detailed description
This is a prospective, pilot, multi-center, double-blinded, randomized post-market study to assess the effect of left ventricular lead pacing location (guided via QLV measurement vs. standard of care approach) in non-LBBB patients. In the QLV arm the physician will: 1. Assess two branches of the coronary sinus - a non-traditional vessel (inclusive of the anterior region) will be tested first and a traditional free lateral branch will be tested second for LV lead placement. 2. Measure QLV for each of the four cathodes of the left ventricular lead in each branch. 3. Choose the vein branch and cathode with the longest QLV measurement and program a vector based on that cathode. In the standard of care group, the left ventricular lead placement will be carried out according to the physician's standard of care implant approach. The impact of the left ventricular lead position will be evaluated based on the patient's response to CRT utilizing the Clinical Composite Score (cardiovascular death, heart failure hospitalizations, New York Heart Association (NYHA) class, and Patient Global Assessment). Authorized site personnel conducting the NYHA class assessment and Patient Global Assessment will be blinded to the randomization assignment and lead implant technique.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | QLV based implant strategy | |
| DEVICE | Standard of care implant strategy |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2013-11-13
- Last updated
- 2019-03-13
- Results posted
- 2019-01-02
Locations
32 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT01983293. Inclusion in this directory is not an endorsement.